FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB API	PROVAL						
OMB Number:	3235-0287						
Estimated average burden							
hours per response	e: 0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  EMSTER KURT VON					2. Issuer Name and Ticker or Trading Symbol  CRISPR Therapeutics AG [ CRSP ]								(Ched	ck all app	all applicable)  Director		. ,	Issuer Owner	
(Last) (First) (Middle) C/O CRISPR THERAPEUTICS, INC. 200 SIDNEY STREET  (Street) CAMBRIDGE MA 02139					3. Date of Earliest Transaction (Month/Day/Year) 08/22/2017									Officer (give title below)				er (specify w)	
					4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)					son	
(5	itate)	(Zip)																	
	Та	ble I - N	lon-Deriv	ative	Sec	uritie	s Ac	quire	d, Di	sposed o	f, or B	enefic	ially	Owne	ed				
Date		Date		Execution Date,		ate,							Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	(A) or (D)	Price		Transac	ction(s)			(111501. 4)	
Common Shares 08/			08/22/2	017	)17			S <sup>(1)</sup>		10,954	D	\$18.5	18.53(2)		2,069,186		T I	See Footnote <sup>(3)</sup>	
Common Shares 08/			08/23/2	)17				S <sup>(1)</sup>		7,035	D	\$18.5	3.53 <sup>(4)</sup> 2,		2,062,151		I	See Footnote <sup>(3)</sup>	
		Table II												wned					
rivative curity or Exercise (Month/Day/Year) Execution Date, if any (Month/Day/Year) Price of Derivative Security						of Expiration			ation D	ate Year)  Amount of Securities Underlying Derivative Security (Ir and 4)  Amount Or Nu Expiration		t of ies ying ive y (Instr. 3 Amount or Number	Derivati Security (Instr. 5		derivative Securities Beneficial Owned Following Reported	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
	(F PR THEF EY STRE DGE M (S curity (Ins hares hares	(First) PR THERAPEUTICS, I EY STREET  DGE MA  (State)  Ta  curity (Instr. 3)  hares  A. Transaction Date (Month/Day/Yea Price of Derivative (Month/Day/Yea	(First) (Middle) PR THERAPEUTICS, INC. EY STREET  OGE MA 02139  (State) (Zip)  Table I - N  curity (Instr. 3)  hares  hares  Table II  2. Conversion or Exercise (Month/Day/Year) of Executif any (Month) Derivative of Derivative (Month/Day/Year)	(First) (Middle) PR THERAPEUTICS, INC. EY STREET  OGE MA 02139  (State) (Zip)  Table I - Non-Deriv Curity (Instr. 3) 2. Transact Date (Month/Day)  hares 08/22/2  Table II - Derivat (e.g., properties of Date (Month/Day)/Year)  Conversion or Exercise Price of Derivative (Month/Day)/Year)	R KURT VON  (First) (Middle)  PR THERAPEUTICS, INC.  EY STREET  OGE MA 02139  (State) (Zip)  Table I - Non-Derivative curity (Instr. 3)  2. Transaction Date (Month/Day/Year)  hares  08/22/2017  Table II - Derivative S (e.g., puts, concentration of Derivative Security  2. Transaction Date (Month/Day/Year)  Mares  08/23/2017  Table II - Derivative S (e.g., puts, concentration Date (for it any (Month/Day/Year))  (Month/Day/Year)  (Month/Day/Year)	(First) (Middle) PR THERAPEUTICS, INC. EY STREET  Table I - Non-Derivative Security (Instr. 3)  CRISP  3. Date of 08/22/20  4. If Amendation Date (Month/Day/Year)  Price of Derivative Security  Table II - Derivative Security (e.g., puts, calls, fary (Month/Day/Year)  3. Date of 08/22/2017  4. If Amendation Date (Month/Day/Year)  2. Transaction Date (L.g., puts, calls, fary (Month/Day/Year)  3. Date of 08/22/2017  4. If Amendation Date (Month/Day/Year)  Security  Table II - Derivative Security (e.g., puts, calls, fary (Month/Day/Year)  (Month/Day/Year)  A. Deemed Execution Date, fary (Month/Day/Year)  (Month/Day/Year)	(First) (Middle) PR THERAPEUTICS, INC. EY STREET  Table I - Non-Derivative Securities (Month/Day/Year)  (State) (Zip)  Table I - Non-Derivative Securities (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  hares  08/22/2017  Table II - Derivative Securities. (e.g., puts, calls, warr.  (e.g., puts, calls, warr.  2. Conversion or Exercise Porice of Derivative Security  (Month/Day/Year)  A. Deemed Execution Date, if any (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  A. Deemed Execution Date, if any (Month/Day/Year)  (A) on Disp of (D) (Instr. 8)	(First) (Middle)  (First) (Middle)  PR THERAPEUTICS, INC.  EY STREET  (State) (Zip)  Table I - Non-Derivative Securities Accurity (Instr. 3)  (Month/Day/Year)  Table II - Derivative Securities Acques.  (e.g., puts, calls, warrants, (Month/Day/Year)  (Month/Day/Year)  Table II - Derivative Securities Acques.  (e.g., puts, calls, warrants, (Month/Day/Year)  (Month/Day/Year)  Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)  (Instr. 3, 4 and 5)	CRISPR Therapeutic  (First) (Middle) PR THERAPEUTICS, INC. EY STREET  OGE MA 02139  (State) (Zip)  Table I - Non-Derivative Securities Acquire Curity (Instr. 3)  Date of Earliest Transaction 08/22/2017  4. If Amendment, Date of Origin 2A. Deemed Execution Date, if any (Month/Day/Year) (Month/Day/Year)  Phares  O8/22/2017  S(1)  Table II - Derivative Securities Acquired, (e.g., puts, calls, warrants, optic 2A. Deemed Execution Date, if any (Month/Day/Year)  Table II - Derivative Securities Acquired, (e.g., puts, calls, warrants, optic 2A. Deemed Execution Date, if any (Month/Day/Year)  Table II - Derivative Securities Acquired, (e.g., puts, calls, warrants, optic 2A. Deemed Execution Date, if any (Month/Day/Year)  Table II - Derivative Securities Acquired, (e.g., puts, calls, warrants, optic 2A. Deemed Execution Date, if any (Month/Day/Year)  Table II - Derivative Securities Acquired, (e.g., puts, calls, warrants, optic 2A. Deemed Execution Date, if any (Month/Day/Year)  OBS (1)  Date (Instr. 3, 4 and 5)  Date Date (Month/Day/Year)	(First) (Middle) PR THERAPEUTICS, INC. EY STREET  OGE MA  02139  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Diate (Month/Day/Year)  Curity (Instr. 3)  2. Transaction Date (Month/Day/Year)  (Month/Day/Year)  A lif Amendment, Date of Original File Execution Date, if any (Month/Day/Year)  (Month/Day/Year)  A lif Amendment, Date of Original File Execution Date, if any (Month/Day/Year)  Scourity (Instr. 3)  Table II - Derivative Securities Acquired, Dispensed of (D) (Instr. 3, 4 and 5)  A peemed Execution Date, if any (Month/Day/Year)  Scourities Acquired, Dispensed of (D) (Instr. 3, 4 and 5)  Date  Date	CRISPR Therapeutics AG CRSP  (First) (Middle) PR THERAPEUTICS, INC.  EY STREET  A. If Amendment, Date of Original Filed (Month/Day/Year)  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of Code (Instr. 3)    2. Transaction Date (Month/Day/Year)   2. A. Deemed Execution Date, (Month/Day/Year)   3. Deemed Execution Date, (Month/Day/Year)   5. Derivative Securities Acquired, Disposed of Code (Instr. 3)    2. Transaction Date (Month/Day/Year)   5. Derivative Securities Acquired, Disposed of Code (Instr. 3)    3. Transaction Date (e.g., puts, calls, warrants, options, convertibe of Derivative Security (Month/Day/Year)   6. Date Exercisable and Expiration Date (A) or Disposed of (D) (Instr. 3, 4 and 5)    3. Transaction Date (Month/Day/Year)   6. Date Exercisable and Expiration Da	CRISPR Therapeutics AG [ CRSP ]  (First) (Middle) PR THERAPEUTICS, INC.  EY STREET  OGE MA 02139  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Ecurity (Instr. 3)  2. Transaction Date (Month/Day/Year) (Month/Day/Year)  (Month/Day/Year)  Date  08/22/2017  2. Transaction Date (Month/Day/Year) (Month/Day/Year)  Date  08/22/2017  Table II - Derivative Securities Acquired, Disposed of, or Ber (e.g., puts, calls, warrants, options, convertible security or Disposed of (D) (Instr. 3, 4 and 5)  Table II - Date Expiration Date (A) or Disposed of (D) (Instr. 3, 4 and 5)  Date  Execution Date (A) or Disposed of, or Ber (E.g., puts, calls, warrants, options, convertible security (A) or Disposed of (D) (Instr. 3, 4 and 5)  Date Expiration Date (A) or Disposed of (D) (Instr. 3, 4 and 5)	CRISPR Therapeutics AG [ CRSP ]  (First) (Middle) PR THERAPEUTICS, INC.  EY STREET  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Benefic Date (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Code V Amount (A) or Disposed Of, or Benefic Date (Month/Day/Year)  (Code V Amount (A) or Disposed Of, Or Benefic Date (e.g., puts, calls, warrants, options, convertible securities acquired, Disposed Of, Or Benefic Date (e.g., puts, calls, warrants, options, convertible securities Date (Month/Day/Year)  (Month/Day/Year)	CRISPR Therapeutics AG [ CRSP ]  (Chec X  (Chec	CRISPR Therapeutics AG CRSP Conversion (Month/Day/Year)  Table I - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)	CRISPR Therapeutics AG [ CRSP ]  (Check all applicable) X Director Officer (give title below)  CRISPR Therapeutics AG [ CRSP ]  (Check all applicable) X Director Officer (give title below)  All Mamendment, Date of Original Filed (Month/Day/Year)  (State)  (State)  (State)  (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned  Curity (Instr. 3)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Check all applicable) X Director Officer (give title below)  (A. Hamendment, Date of Original Filed (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Check all applicable) X Director Officer (give title below)  (A. Hamendment, Date of Original Filed (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Check all applicable) X Director Officer (give title below)  (A. Hamendment, Date of Original Filed (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Check all applicable) X Director Officer (give title below)  (A. Hamendment, Date of Original Filed (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Check all applicable) X Director Officer (give title below)  (A. Hamendment, Date of Original Filed (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Check all applicable) A. Hamendment, Date of Original Filed (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Check all applicable) A. Hamendment, Date of Original Filed (Month/Day/Year)  (Month/Day/	CRISPR Therapeutics AG CRSP CRSP CRSP (Check all applicable)  (First) (Middle)  (First) (Middle)  (First) (Middle)  (Refresh Carrier Conversion	CRISPR Therapeutics AG [ CRSP ]  CRISPR Therapeutics AG [ CRSP ]	

## **Explanation of Responses:**

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP ("Abingworth") on May 15, 2017.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$18.50 to \$18.75 per share, inclusive. Kurt von Emster (the "Reporting Person") undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
- 3. These shares are held by Abingworth. Abingworth Bioventures VI GP LP ("Abingworth GP") serves as the general partner of Abingworth. Abingworth General Partner VI LLP, serves as the general partner of Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by Abingworth. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his
- 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$18.50 to \$18.60 per share, inclusive. The Reporting Person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

/s/ John Heard, as attorney-in-08/24/2017 **fact** 

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.